S
688247
vs
S
Shanghai Composite
Over the past 12 months, Sinotherapeutics Inc has underperformed Shanghai Composite, delivering a return of -6% compared to the Shanghai Composite's +23% growth.
Stocks Performance
688247 vs Shanghai Composite
Performance Gap
688247 vs Shanghai Composite
Performance By Year
688247 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sinotherapeutics Inc
Glance View
Sinotherapeutics, Inc. engages in the research and development, production and sales of high-end generic drugs and Contract Research Organization (CRO) services. The company is headquartered in Shanghai, Shanghai and currently employs 248 full-time employees. The company went IPO on 2022-08-25. The firm's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The firm mainly operates in the domestic market and overseas markets.